Cargando…

Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?

Detalles Bibliográficos
Autores principales:	Pitt, Bertram, Weir, Matthew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063125/ https://www.ncbi.nlm.nih.gov/pubmed/26634417 http://dx.doi.org/10.1002/ejhf.452

Ejemplares similares

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments
por: Zannad, Faiez, et al.
Publicado: (2019)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy
por: Murphy, Daniel, et al.
Publicado: (2022)

Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN
por: Pitt, Bertram, et al.
Publicado: (2018)

Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!
por: Rossignol, Patrick, et al.
Publicado: (2023)

Left bundle branch block in serious hyperkalaemia: rate-dependency?
por: Joustra, R., et al.
Publicado: (2016)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, Eberhard, et al.
Publicado: (2013)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
por: Slawik, Jonathan, et al.
Publicado: (2020)

Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure
por: Maggioni, Aldo P., et al.
Publicado: (2021)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
por: Henrysson, Josefin, et al.
Publicado: (2022)

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
por: Ward, Thomas, et al.
Publicado: (2022)

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022)

Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review
por: Rossignol, Patrick, et al.
Publicado: (2019)

Management of hyperkalaemia in adults.
por: McVeigh, G.
Publicado: (2005)

Frequency and clinical impact of hyperkalaemia within a large, modern, real‐world heart failure population
por: Muhlestein, Joseph B., et al.
Publicado: (2020)

New treatments for hyperkalaemia: clinical use in cardiology
por: Vijayakumar, Shilpa, et al.
Publicado: (2019)

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, E., et al.
Publicado: (2013)

Severe hyperkalaemia: demographics and outcome
por: Phillips, B.M., et al.
Publicado: (2014)

Surreptitious hyperkalaemia and its complications
por: Morgenstern, Tilo, et al.
Publicado: (2009)

Potassium homoeostasis and pathophysiology of hyperkalaemia
por: Kjeldsen, Keld Per, et al.
Publicado: (2019)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
por: Antoniou, Tony, et al.
Publicado: (2011)

Surgical treatment of quadruple valve endocarditis in a patient with heart failure
por: Milicic, Miroslav, et al.
Publicado: (2023)

Letter to the editor: Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: The contribution of previous heart failure to heart failure hospitalization may be overestimated
por: Mei, Kaibo, et al.
Publicado: (2023)

Current treatment and unmet needs of hyperkalaemia in the emergency department
por: Rafique, Zubaid, et al.
Publicado: (2019)

Alternative Models of Cardiac Rehabilitation Delivery Urgently Needed to Improve Access for Heart Failure Patients
por: Taylor, Rod S., et al.
Publicado: (2021)

Ivabradine tolerability in heart failure
por: Birkhoelzer, Sarah, et al.
Publicado: (2018)

Hypoalbuminemia in Patients with Acute Decompensated Heart Failure
por: Imamura, Teruhiko
Publicado: (2019)

Smartphone and email capabilities of heart failure patients
por: Campbell, Gayle, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
por: Triposkiadis, Filippos, et al.
Publicado: (2022)

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
por: Ward, Thomas, et al.
Publicado: (2023)

Hyperkalaemia: aetiology, epidemiology, and clinical significance
por: Tromp, Jasper, et al.
Publicado: (2019)

Suxamethonium-chloride: Hyperkalaemia: case report
Publicado: (2021)

Reply: Alternative Models of Cardiac Rehabilitation Delivery Urgently Needed to Improve Access for Heart Failure Patients
por: Keshvani, Neil, et al.
Publicado: (2021)

How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
por: Humphrey, Toby, et al.
Publicado: (2021)

Increased mortality in elderly heart failure patients receiving infusion of furosemide compared to elderly heart failure patients receiving bolus injection
por: Sager, Rana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6c3gqses1n7u7iia65qipqfvi3